UK ranks 22nd out of 29 comparable countries for survival of Brain Cancer
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.